Explore › Outcome › Urinary tract infection
Outcome

Urinary tract infection

Also known as: Infection - urinary NOS Infection of urinary tract Infection, Urinary Tract Infections, Urinary Tract Tract Infection, Urinary Tract Infections, Urinary URINARY TRACT INFECT UTI - Urinary tract infection Urinary Tract Infection Urinary Tract Infections Urinary infection NOS Urinary infection NOS (disorder) +13 more
3 findings 1 paper 3 related entities View in graph →

Related entities

interventions
OnabotulinumtoxinA 200 unit powder for solution for injection vial1
conditions
urgency urinary incontinence1
studys
PMC53994191

Findings (27)

None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →
None
adverse

Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001),

Effect: adverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%

Size: 35% vs 11%; risk difference, -23% CI: 95% CI, -33% to -13%
PMC5399419
Finding details → · Paper → · Graph →

Papers (1)